This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health Professions Council as evidence of ongoing continual professional development....
Multiple risk factors for both venous thromboembolism (VTE) and early mortality in patients with lung cancer receiving systemic chemotherapy should guide best practice by better informing clinical evaluation and treatment decision‐making. The Khorana risk score is of value in assessing the risk of early all‐cause mortality along with other clinical parameters in patients with lung cancer receiving systemic therapy. Further study is needed to fully evaluate the validity of the risk score in predicting the risk of VTE in the modern era of lung cancer therapy.
At the European Society for Medical Oncology (ESMO) 2017 Congress, held September 8-12, 2017, in Madrid, Spain, the theme was "integrating science into oncology for a better patient outcome." In this ESMO 2017 Special Report, The Oncologist focuses on new research on the use of prognostic and predictive biomarkers in the individualized management of patients with colorectal cancer.
>The addition of the heat shock protein 27 (Hsp27)‐targeting antisense oligonucleotide, apatorsen, to a standard first‐line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer.
> Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.
Conference Perspectives: Lessons Learned
Evolving Standards in Colorectal Cancer: Case-Based Insights from ESMO 2017
David P. Ryan, MD, explores new standards of care in advanced and metastatic colorectal cancer (mCRC).